
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | $8.23B+7.2% | $7.68B+3.8% | $7.39B+6.5% | $6.94B+1.6% | $6.83B+11.4% | $6.13B-23.2% | $7.98B+0.6% | $7.93B+1.7% | $7.80B |
| Cost of products sold, excluding intangible asset amortization | $2.49B+13.8% | $2.19B+5.2% | $2.08B+3.2% | $2.02B+3.0% | $1.96B+7.5% | $1.82B-19.0% | $2.25B-0.8% | $2.27B+6.5% | $2.13B |
| Intangible asset amortization | $665.9M+12.5% | $591.9M+5.4% | $561.5M+6.6% | $526.8M-0.5% | $529.5M+3.4% | $512.1M-12.4% | $584.3M-1.9% | $595.9M-1.3% | $603.9M |
| Research and development | $458.5M+4.8% | $437.4M-4.6% | $458.7M+13.0% | $406.0M-6.8% | $435.8M+35.0% | $322.8M-28.2% | $449.3M+14.7% | $391.7M+5.9% | $369.9M |
| Selling, general and administrative | $3.26B+11.2% | $2.93B+3.2% | $2.84B+2.8% | $2.76B-2.9% | $2.84B+4.8% | $2.71B-18.9% | $3.34B-1.1% | $3.38B+8.8% | $3.10B |
| Restructuring and other cost reduction initiatives | $181.2M-17.3% | $219.0M+44.2% | $151.9M-20.7% | $191.6M+52.4% | $125.7M+17.3% | $107.2M+114.4% | $50.0M+46.2% | $34.2M+94.3% | $17.6M |
| Acquisition, integration, divestiture and related | $76.9M+225.8% | $23.6M+8.8% | $21.7M+90.4% | $11.4M+267.7% | $3.1M-72.8% | $11.4M-6.6% | $12.2M | — | — |
| Operating expenses | $7.13B+11.6% | $6.39B+4.5% | $6.12B-2.0% | $6.24B+4.6% | $5.97B-1.3% | $6.04B-11.7% | $6.84B-13.3% | $7.90B+12.8% | $7.00B |
| Operating Profit | $1.10B-14.6% | $1.29B+0.6% | $1.28B+83.5% | $696.3M-19.1% | $860.3M+935.3% | $83.1M-92.7% | $1.14B+3265.4% | $33.8M-95.8% | $799.3M |
| Other income (expense), net | $25.5M+182.0% | -$31.1M-234.4% | -$9.3M+92.7% | -$128.0M-1149.2% | $12.2M-48.7% | $23.8M+595.8% | -$4.8M+69.2% | -$15.6M-66.0% | -$9.4M |
| Interest expense, net | -$292.8M-34.3% | -$218.0M-8.3% | -$201.2M-22.1% | -$164.8M+20.9% | -$208.4M+1.7% | -$212.1M+6.5% | -$226.9M+21.6% | -$289.3M+11.1% | -$325.3M |
| Earnings before income taxes | $830.8M-19.9% | $1.04B-2.9% | $1.07B+164.5% | $403.5M-19.1% | $499.0M+574.3% | -$105.2M-111.6% | $905.8M+434.1% | -$271.1M-158.4% | $464.6M |
| Provision for income taxes | $125.7M-4.3% | $131.4M+211.4% | $42.2M-62.4% | $112.3M+109.9% | $53.5M+155.7% | -$96.0M+57.5% | -$225.7M-308.6% | $108.2M+108.0% | -$1.35B |
| Net Earnings | $705.1M-22.1% | $905.2M-11.7% | $1.03B+252.0% | $291.2M-34.6% | $445.5M+4942.4% | -$9.2M | — | — | — |
| Less: Net (loss) earnings attributable to noncontrolling interest | -$100K-106.7% | $1.5M+36.4% | $1.1M+10.0% | $1.0M+100.0% | $500K-66.7% | $1.5M | — | — | — |
| Net Earnings of Zimmer Biomet Holdings, Inc. | $705.1M-22.0% | $903.8M-11.7% | $1.02B+342.5% | $231.4M-42.4% | $401.6M+389.1% | -$138.9M-112.3% | $1.13B+398.4% | -$379.2M-120.9% | $1.81B |
| Basic | $198.0M-2.5% | $203.1M-2.7% | $208.7M-0.4% | $209.6M+0.5% | $208.6M+0.8% | $207.0M+0.9% | $205.1M+0.8% | $203.5M+0.8% | $201.9M |
| Diluted | $198.7M-2.6% | $203.9M-2.8% | $209.7M-0.3% | $210.3M-0.0% | $210.4M+1.6% | $207.0M+0.1% | $206.7M+1.6% | $203.5M-0.1% | $203.7M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.